Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.
Flare Therapeutics has raised $123.0M in total funding. The most recent round was Series B. The last funding was announced in March 2023.
Flare Therapeutics's investors include Eli Lilly, Novartis, Invus, Casdin Capital, Pfizer Venture Investments.
Flare Therapeutics is headquartered in Cambridge, United States.
Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.
Flare Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Flare Therapeutics — Funding & Investors." VCBacked, March 22, 2023, https://www.vcbacked.co/company/flare-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). Flare Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/flare-therapeutics
{{cite web |title=Flare Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/flare-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated